As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

Harvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...

Markets traded subdued with the India VIX correcting nearly 15% this week, though this hasn't significantly impacted benchmark index moveme...

As far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...

Delhi's smog is increasingly linked to a rise in rheumatoid arthritis cases, with doctors warning that air pollution is turning the immune ...

Arjun Kapoor's remarkable fitness journey began with shedding over 50 kg before his Bollywood debut. Walking played a crucial role in his w...

According to a 2022 study, the prevalence of hypothyroidism in India is 11%, which is considerably higher than the 2%–4.6% observed in West...

Telugu star Samantha Ruth Prabhu celebrated her 36th birthday by sharing pictures on Instagram, including those of herself receiving hyperb...

Once the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to th...

Biocon's partner US-based Equillium Inc has expanded its 'EQUALISE' study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for Ito...

Drug firm Zydus Cadila on Monday said it has received permission from Drugs Controller General of India (DCGI) to initiate phase-1 clinical...

Below the age of 17 years, only 8% are Covid positive in India.

India doesn't need to be as disrespectful as Trump is. But it must seize the chance for a diplomatic payback.

Autoimmune liver disease can be transmitted genetically or is caused because of some reactions wherein the liver cells are recognised as in...

The R&D division was one of the last assets of the Japanese drug maker in India after it sold its generic pharma business of Ranbaxy to Sun...

Biotechnology major Biocon today said it is looking for partners to develop and market its novel biologic drug Itolizumab

The company had received marketing authorisation for Itolizumab from the Drugs Controller General of India (DCGI) in January, 2013.